Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer

NCT03391934 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

234

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Cetuximab + FOLFIRI

Sponsor

Cinnagen